CLL-Lymphoma
US Focus Meeting 2026
📍 Estancia La Jolla Hotel, 9700 N Torrey Pines Rd, La Jolla, CA 92037
🗓️ May 8 - 9, 2026
Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the CLL-Lymphoma Focus Meeting 2026, to be held on May 8 - 9, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing CLL-Lymphoma research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of CLL-Lymphoma US Focus Meeting 2026:
Susan O’Brien, MD
University of California, Irvine Medical Center, Los Angeles, CA
Christopher Flowers, MD
MD Anderson Cancer Center, Houston, TX
Thanks to our Supporters
Gold
Silver
Additional Support provided by Incyte
Agenda & Faculty
May 8, 2026 | CLL Day
08:00 AM
Registration Opens
Session I
Moderated by: Nicole Lamanna, MD
09:00 AM
Proteomics in CLL
Catherine Wu, MD
Dana-Farber Cancer Institute, Boston, MA
09:20 AM
How I Choose Frontline Therapy for Which Patient
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
09:40 AM
Where Does Pirtobrutinib Fit in Now?
Mahesh Swaminathan, MD
MD Anderson Cancer Center, Houston, TX
10:00 AM
Panel Discussion
10:30 AM
Coffee Break
Session II
Moderated by: Matthew Davids, MD
10:50 AM
CAR-T in CLL
David Maloney, MD
Fred Hutchinson Cancer Research Center, Seattle, WA
11:10 AM
BTKI + BCL2i Combinations in CLL
Mazyar Shadman, MD
Fred Hutchinson Cancer Research Center, Seattle, WA
11:30 AM
Survivorship in CLL
Alessandra Ferrajoli, MD
MD Anderson Cancer Center, Houston, TX
11:50 AM
Panel Discussion
12:20 PM
Industry Supported Independent Expert Discussion Supported by Lilly
01:05 PM
Lunch Break + Faculty and Fellow Photo
Session III
Moderated by: Nitin Jain, MD
01:55 PM
Treatment of Patients with P53 Aberrations
Nicole Lamanna, MD
The Herbert Irving Comprehensive Cancer Center, New York, NY
02:15 PM
Update on Richters
Meghan Thompson, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
02:35 PM
Is the Use of MRD Standard of Care in CLL?
Versha Banerji, MD
Cancer Care Manitoba, Winnipeg, Canada
02:55 PM
Panel Discussion
03:25 PM
Coffee Break
Session IV
Moderated by: Alessandra Ferrajoli, MD
03:45 PM
BTK Degraders
Matthew Davids, MD
Dana-Farber Cancer Institute, Boston, MA
04:05 PM
Bispecifics in CLL
Bita Fakhri, MD
Stanford Medicine, CA
04:25 PM
Future Questions in CLL
Jennifer Brown, MD
Dana-Farber Cancer Institute, Boston, MA
04:45 PM
Panel Discussion
05:15 PM
Adjourn
May 9, 2026 | Lymphoma Day
08:30 AM
Registration Opens
Session V: Biomarkers, MRD Precision Tools in Lymphoma
Moderated by: Laura Hilton, PhD
09:00 AM
Cell-Free DNA in Lymphoma: From Detection to Decision-Making
Ash Alizadeh, MD
Stanford Medicine, CA
09:20 AM
MRD and Risk-Adapted Approaches in LBCL and FL
Jordan S. Goldstein, MD
Stanford Medicine, CA
09:40 AM
Genetic Subtype-Guided Trials Clinical Application in 2026
Laura Hilton , MD
BC Cancer Agency, Vancouver, Canada
10:00 AM
Panel Discussion: Genomic-Based Therapy Selection for DLBCL– Are We Ready?
10:30 AM
Coffee Break
Session VI: Frontline and Relapsed LBCL - State of the Art
Moderated by: Elizabeth Budde, MD
10:50 AM
Tailoring First-Line Therapy in LBCL: Pola-R-CHP and Beyond
Pre-Recorded Talk
Sarah Rutherford, MD
Weill Cornell Medicine, New York, NY
11:10 AM
Innovative Strategies in Relapsed/ Refractory DLBCL
Dai Chihara, MD
MD Anderson Cancer Center, Houston, TX
11:30 AM
Bispecific Abs in First and Second Line Therapy for DLBCL
Elizabeth Budde, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
11:50 AM
Panel Discussion: Matching Risk to Strategy in DLBCL
12:20 PM
Lunch Break + Faculty and Fellows Photo
Session VII: Clinical Trial Design & Regulatory Innovation
Moderated by: Dai Chihara, MD
01:10 PM
Using Real-World Evidence (RWE) in Lymphoma Drug Development
Christopher Flowers, MD
MD Anderson Cancer Center, Houston, TX
01:30 PM
Biomarker Driven Trials: Smarter Endpoints, Learner Designs
Michael R. Green, PhD
MD Anderson Cancer Center, Houston, TX
01:50 PM
Clinician's View: What Makes a Trial Practically Useful?
Tycel Phillips, MD
City of Hope, Duarte, CA
02:10 PM
Panel Discussion: Can Trail Design Keep Pace with Discovery?
02:40 PM
Coffee Break
Session VIII: TBD
Moderated by: Pamela Allen, MD
03:00 PM
Novel Targets in PTCL: Clinical Update
Luis Malpica Castillo, MD
MD Anderson Cancer Center, Houston, TX
03:20 PM
Cutaneous T-Cell Lymphoma: Emerging Therapies and Trials
Pamela Allen, MD
Winship Cancer Institute of Emory University, Georgia
03:40 PM
CNS Lymphoma: What's New in Targeted Approaches?
Ayushi Chauhan, MD
Wellstar MCG Health, Georgia
04:00 PM
Panel Discussion
04:30 PM
Adjourn
Neve Rowlands
Project Manager
How long has Neve Rowlands been in the business?
Neve Rowlands has been with MD Education since 2023.
About Neve Rowlands
I am a dedicated project manager in the hematology industry, with a current focus on CLL and lymphoma. Specialising in logistical organisation with a sharp eye for detail, and committed to delivering high-quality, seamless events. The most rewarding part of the role is watching meetings come to life. I am passionate about connecting with both familiar and new faces, and driven by the impact of well-executed projects that support meaningful progress in the field.
